+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating Risvutatug rezetecan Ris-Rez, a new medicine targeting specific proteins B7-H3 on cancer cells, in people with relapsed small cell lung cancer SCLC. The study compares Ris-Rez with the standard treatment topotecan to see if Ris-Rez can shrink tumors or make them disappear and if it helps participants live longer. It also examines the safety and side effects of both treatments to better understand their impact. Participants with relapsed SCLC will be randomly assigned to receive either Ris-Rez or topotecan. Both treatments will be administered according to standard protocols, with Ris-Rez provided as a biological therapy and topotecan as a drug treatment. The study is open-label, meaning both participants and researchers know which treatment is given. During the study, participants will be monitored through various assessments including survival time, tumor response, symptom changes, brain progression, and quality of life measures. Safety will be closely tracked through adverse event reports, laboratory tests, heart function evaluations, and immune response monitoring. The main outcome focuses on overall survival, with follow-up extending up to approximately 113 weeks to capture long-term effects and responses.

Age: 18Years +All GendersPhase 3
144 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.

Age: 18Years +All GendersPhase 3
283 locations
E

Actively Recruiting

Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.

Age: 18Years +All GendersPhase 3
433 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
C

Actively Recruiting

Researchers are comparing the safety and effectiveness of laparoscopic cholecystectomy versus a wait-and-see approach in elderly patients who have had successful endoscopic removal of common bile duct stones. The study aims to determine if waiting without immediate surgery is not worse than having the gallbladder removed laparoscopically. The main goal is to observe death, major postoperative complications, or recurrent biliary disease within one year after randomization. Four hundred participants aged 75 or older with cleared bile duct stones are randomly assigned to one of two groups. One group receives laparoscopic cholecystectomy within two weeks after stone removal, while the other group is managed without surgery initially but can have cholecystectomy later if needed. An interim safety analysis is planned after 100 participants to ensure no significant differences arise between groups. The trial may end early if strong evidence shows a difference in outcomes. Participants are followed for up to one year after randomization to track the composite outcome of death, major complications, or biliary events. Researchers also monitor quality of life, survival, healthcare costs, and pain related to biliary issues at various time points. The study includes assessments at 30, 180, and 365 days, with additional monitoring of hospitalizations and complications extending to two years in some measures.

Age: 75Years +All GendersPhase Not Applicable
12 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness of different methods to help people stop smoking combined with low-dose CT LDCT screening for lung cancer. It focuses on individuals aged 50 to 74 who have a significant smoking history and are current smokers. The study compares smoking cessation methods, the impact of LDCT screening on lung cancer detection, the stage at which lung cancer is found, and survival specific to lung cancer. Participants are randomly assigned to one of three groups smoking cessation using a smartphone application plus LDCT screening, smoking cessation using written materials plus LDCT screening, or smoking cessation with the smartphone application alone without LDCT screening. The interventions involve digital support for quitting smoking and lung cancer screening using low-dose CT scans. The study tracks outcomes over time, including smoking cessation rates and lung cancer findings. During the study, researchers will monitor smoking cessation success at three, 12, and 24 months, verify smoking status with carbon monoxide measurements, and assess lung cancer incidence and screening results at various time points including up to ten years. Participants will be asked to use the assigned smoking cessation method and, if applicable, undergo LDCT scans. The study lasts several years to capture both short- and long-term outcomes related to smoking behavior and lung cancer detection.

Age: 50Years - 74YearsAll GendersPhase Not Applicable
5 locations
S

Actively Recruiting

Researchers are studying the safety and effectiveness of a medicine called MK-1084 in treating Non-Small Cell Lung Cancer NSCLC with a specific gene change known as KRAS G12C. This study aims to find out how many participants experience tumor shrinkage or disappearance while receiving this treatment. The study is a Phase 2 trial focused on advanced or metastatic nonsquamous NSCLC with this genetic mutation. Participants receive one of three treatments Pembrolizumab plus MK-1084 Pembrolizumab, MK-1084, and Cetuximab or Pembrolizumab, MK-1084, and sacituzumab tirumotecan sac-TMT. Pembrolizumab is given intravenously every 6 weeks, MK-1084 is taken orally, and Cetuximab or sac-TMT are given intravenously every 2 weeks depending on the assigned group. Rescue medications are also provided to reduce side effects like infusion reactions and mouth sores. During the study, participants undergo evaluations for side effects and tumor response at various time points, including up to approximately 84 months for long-term safety and effectiveness monitoring. Researchers assess dose-limiting toxicities, adverse events, and how many participants stop treatment because of side effects. Tumor response is measured using established criteria, and blood samples are collected to study MK-1084 levels. The total study duration extends until 2032, allowing for extended follow-up.

Age: 18Years +All GendersPhase 2
39 locations
N

Actively Recruiting

Researchers are studying nonoperative management NOM for patients with rectal cancer who achieve a complete clinical response after neoadjuvant therapy. This single-arm, international trial aims to establish a unified NOM protocol and evaluate oncological outcomes, such as organ preservation and local regrowth rates, in Finnish and Estonian treatment settings compared to global experiences. Participants with confirmed complete clinical response will receive nonoperative surveillance including clinical examinations, rectal MRI, endoscopy, and body CT scans. The study involves close monitoring every 3 months during the first 2 years and every 6 months thereafter up to 5 years. No randomization is involved, and treatment aligns with Nordic practice standards. During the trial, participants will undergo regular clinical and imaging assessments to monitor for local regrowth or distant spread. Researchers will measure disease-free survival at 2 years as the primary outcome, alongside secondary outcomes such as overall survival, quality of life, and complication rates up to 5 years. Data will be securely collected and monitored as part of standard care, with safety procedures in place for local recurrence events.

Age: 18Years +All GendersPhase Not Applicable
13 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating whether parent-performed digital otoscopy at home, combined with artificial intelligence AI analysis of images, can reduce doctor visits for suspected acute otitis media AOM in young children. AOM is a common ear infection that often leads to healthcare visits, but diagnosing it accurately can be challenging and depends on clinical expertise. This pilot randomized controlled trial aims to assess the feasibility, diagnostic accuracy of trained parents, and the impact on antibiotic use and healthcare resources. Parents in the intervention group receive a digital otoscope device and training on how to interpret images of their childs eardrum. They perform home ear exams when they suspect infection, capture images or videos, and record symptoms in a diary. If signs of AOM or illness appear, medical evaluation is advised. The control group follows standard care without home otoscopy but keeps the same symptom diary. The study uses AI to analyze images and compares parent interpretations, AI results, and expert evaluations. Participants are children aged 12 to 47 months with at least one AOM episode in the past year. The study lasts 5 to 9 months per child depending on enrollment date. Data is collected through symptom diaries, monthly questionnaires, health records, and stored images. Researchers will measure the number of physician visits due to suspected AOM, agreement between parent, AI, and expert diagnoses, antibiotic use, adverse events, complications, daycare absences, parental work absences, and satisfaction. Safety and data privacy are carefully managed following regulations.

Age: 12Months - 47MonthsAll GendersPhase Not Applicable
2 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of combining gedatolisib with palbociclib and endocrine therapy compared to endocrine therapy with ribociclib for treating adults with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. This Phase 3, open-label, randomized clinical trial focuses on patients who are either endocrine-resistant or endocrine-sensitive based on their cancer progression and prior treatments. Participants will be assigned based on endocrine sensitivity status to one of two studies. Study 1 includes patients with endocrine-resistant cancer receiving either gedatolisib plus palbociclib and fulvestrant or ribociclib with fulvestrant. Study 2 includes endocrine-sensitive patients treated with gedatolisib plus palbociclib and letrozole or ribociclib plus letrozole. Gedatolisib is given intravenously once weekly for three weeks followed by a week off. Palbociclib and ribociclib are taken orally on days 1 to 21 of each 28-day cycle. Fulvestrant is administered by intramuscular injection every 2 to 4 weeks, while letrozole is taken orally daily. Throughout the study, participants undergo regular assessments including scans and laboratory tests to monitor disease progression and safety. Researchers measure outcomes such as progression-free survival, overall survival, response rates, duration and time to response, clinical benefits, quality of life, and adverse events over approximately 48 months. The trial includes screening to confirm eligibility and ongoing monitoring during and after treatment to evaluate the treatments effects and safety.

Age: 18Years +All GendersPhase 3
239 locations

1-10 of 13

1